⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7343990 | 0.92 | NOS2 (0.31) | — | |
| SCHEMBL28838385 | 0.80 | LMNA (0.30) | — | |
| SCHEMBL12653525 | 0.72 | — | — | |
| SCHEMBL7022084 | 0.72 | — | — | |
| SCHEMBL17056242 | 0.72 | — | — | |
| SCHEMBL8785012 | 0.67 | NOS2 (0.30) | — | |
| SCHEMBL669567 | 0.63 | — | — | |
| SCHEMBL30130597 | 0.61 | MAPK1 (0.35) | — | |
| SCHEMBL25476957 | 0.61 | CA1 (0.32) | — | |
| SCHEMBL229131 | 0.60 | MAOA (0.31) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1141 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250129085-A1 | SUBSTITUTED IMIDAZO[1,2-B]PYRIDAZINES AS PROTEIN KINASE INHIBITORS | SUMITOMO PHARMA AMERICA INC (US) | 2025-04-24 | — | — | US | claimed |
| US-20150141378-A1 | NITROXYL PROGENITOR COMPOUNDS AND METHODS OF USE | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2015-05-21 | — | — | US | claimed |
| US-20130210821-A1 | Methods for Treating Obesity | ZAFGEN, INC. | 2013-08-15 | — | — | US | claimed |
| JP-4851337-B2 | — | — | 2012-01-11 | — | — | JP | claimed |
| US-20110301163-A1 | QUINOLINE COMPOUNDS AS INHIBITORS OF ANGIOGENESIS, HUMAN METHIONINE AMINOPEPTIDASE, AND SIRT1, AND METHODS OF TREATING DISORDERS | THE JOHNS HOPKINS UNIVERSITY (US) | 2011-12-08 | — | — | US | claimed |
| US-RE43003-E1 | Epothilone derivatives | BRISTOL-MYERS SQUIBB COMPANY (US) | 2011-12-06 | — | — | US | claimed |
| WO-2011150338-A1 | METHODS OF TREATING OBESITY | ZAFGEN CORPORATION (US) | 2011-12-01 | — | — | WO | claimed |
| EP-2350012-A2 | QUINOLINE COMPOUNDS AS INHIBITORS OF ANGIOGENESIS, HUMAN METHIONINE AMINOPEPTIDASE, AND SIRT1, AND METHODS OF TREATING DISORDERS | The Johns Hopkins University (US) | 2011-08-03 | — | — | EP | claimed |
| US-7935698-B2 | Heteroaryl-hydrazone compounds | SYNTA PHARMACEUTICALS CORPORATION (US) | 2011-05-03 | — | — | US | claimed |
| US-RE41895-E1 | [1S-[1R*,3R*(E),7R*,10S*,11R*,12R*,16S*]]-7,11-Dihydroxy-8,8,10,12,16-pentamethyl-3-[1-methyl-2-(2-methyl-4-thiazolyl)ethenyl]-4,13,17-trioxabicyclo [14.1.0]heptadecane-5,9-dione; treating breast cancer, ovarian cancer, colon cancer, head and neck cancer, lung cancer, gynecological cancers, brain cancer | BRISTOL-MYERS SQUIBB COMPANY (US) | 2010-10-26 | — | — | US | claimed |
| US-20060122156-A1 | Heteroaryl compounds | SYNTA PHARMACEUTICALS CORP. (US) | 2006-06-08 | — | — | US | claimed |
| WO-2006053227-A2 | IL-12 MODULATORY COMPOUNDS | SYNTA PHARMACEUTICALS CORP. (US) | 2006-05-18 | — | — | WO | claimed |
| WO-2006053109-A1 | HETEROARYL COMPOUNDS | SYNTA PHARMACEUTICALS CORP. (US) | 2006-05-18 | — | — | WO | claimed |
| US-20050282809-A1 | Heteroaryl-hydrazone compounds | LSI FINANCING LLC, AS ADMINISTRATIVE AGENT | 2005-12-22 | — | — | US | claimed |
| US-20050250774-A1 | Pyridine compounds | LSI FINANCING LLC, AS ADMINISTRATIVE AGENT | 2005-11-10 | — | — | US | claimed |
| US-20050250770-A1 | Fused heterocyclic compounds | LSI FINANCING LLC, AS ADMINISTRATIVE AGENT | 2005-11-10 | — | — | US | claimed |
| WO-2005046698-A1 | FUSED HETEROCYCLIC COMPOUNDS | SYNTA PHARMACEUTICALS, CORP. (US) | 2005-05-26 | — | — | WO | claimed |
| WO-2005046604-A2 | HETEROARYL-HYDRAZONE COMPOUNDS | SYNTA PHARMACEUTICALS, CORP. (US) | 2005-05-26 | — | — | WO | claimed |
| WO-2005046603-A2 | PYRIDINE COMPOUNDS | SYNTA PHARMACEUTICALS, CORP. (US) | 2005-05-26 | — | — | WO | claimed |
| US-6498257-B1 | 2,3-olefinic epothilone derivatives | BRISTOL-MYERS SQUIBB COMPANY | 2002-12-24 | — | — | US | claimed |